US Patent

US11364260 — Methods and compositions for administration of iron

Method of Use · Assigned to American Regent Inc · Expires 2027-01-08 · 1y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating iron-related conditions using a single unit dosage of at least 0.6 grams of elemental iron via an iron carbohydrate complex.

USPTO Abstract

The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3637 — Injectafer
U-3637 — Injectafer
U-3637 — Injectafer
U-3637 — Injectafer

Patent Metadata

Patent number
US11364260
Jurisdiction
US
Classification
Method of Use
Expires
2027-01-08
Drug substance claim
No
Drug product claim
No
Assignee
American Regent Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.